Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Bacteriology|September 12, 1998
The Bacteroides fragilis BtgA mobilization protein binds to the oriT region of pBFTM10L A Sitailo, A M Zagariya, P J Arnold, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 14, 2005
Clostridium clostridioforme: a mixture of three clinically important speciesS M Finegold, Y Song, C Liu, et al.
American Journal of Surgery|January 1, 1994
Plasmid labeling confirms bacterial translocation in pancreatitisG B Kazantsev, D W Hecht, R Rao, et al.
Anaerobe|May 17, 2006
Characterization of the Bacteroides fragilis pathogenicity island in human blood culture isolatesM C Claros, Z C Claros, D W Hecht, et al.
Anaerobe|November 22, 2016
Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009D R Snydman, N V Jacobus, L A McDermott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2002
Multilaboratory comparison of growth characteristics for anaerobes, using 5 different agar mediaD E Roe, S M Finegold, D M Citron, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2002
Multilaboratory comparison of anaerobe susceptibility results using 3 different agar mediaD E Roe, S M Finegold, D M Citron, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2002
In vitro activities of newer quinolones against bacteroides group organismsD R Snydman, N V Jacobus, L A McDermott, et al.
Antimicrobial Agents and Chemotherapy|October 3, 1999
Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996D R Snydman, N V Jacobus, L A McDermott, et al.
The Journal of Antimicrobial Chemotherapy|October 5, 2015
Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infectionD N Gerding, D W Hecht, T Louie, et al.
Pageof 5